聯合醫務(00722.HK)公佈年度業績 經調整EBITDA升29.6% 末期息2.8港仙
格隆匯9月23日丨聯合醫務(00722.HK)發佈公吿，集團於截至2021年6月30日止財政年度繼續錄得穩健表現。公司的收入由2020財政年度的5.6億港元增加11.7%至6.23億港元，主要由於公司的醫學影像及專科業務線以及健康評估的強勁增長所致。
儘管面對宏觀經濟的不明朗因素，公司適時採取多種措施以減輕疫情對旗下營運造成的不利影響，集團的財務情況維持穩健。公司的經調整EBITDA由2020財政年度的7070萬港元上升29.6%至2021財政年度的9170萬港元，乃主要由於公司的醫學影像及專科業務線以及健康評估的強勁增長而有關業務的利潤率較高，同時公司的企業醫療保健解決方案服務受各企業（尤其是從事旅遊、酒店和零售業者）間的連鎖反應所影響。憑藉公司備受認可的業務及財務實力，董事會建議派發末期股息每股2.8港仙，即全年派息每股3.8港仙（2020財政年度全年股息：每股3.3港仙）。
期間來自香港及澳門臨牀醫療保健服務業務線的收入增加21.9%至4.49億港元（分部間抵銷前），而公司的經營利潤（除税前及除非經常性項目前經營利潤）由3630萬港元增加130.4%至8370萬港元，乃主要由於公司的醫學影像及專科業務線以及健康評估的強勁增長而有關業務的利潤率較高，其為集團的發展焦點及增長領域。
於2022財政年度，於香港中環總建築面積達約11,000平方尺的新旗艦醫務中心將拓展公司的專科業務線，而公司於2021財政年度收購的醫學影像業務將帶來一整年的財務表現貢獻。集團自去年以來將第三方管理服務拓展至公司保險公司客户，擴大聯合醫務的企業醫療保健解決方案範圍。聯合醫務旨在通過完善及多個不同專科的UMP網絡，提供便捷、可靠、協調、全面及實惠的醫療保健服務。於2021年6月30日，UMP網絡包括超過1,100個位於香港及澳門的服務點。
中國內地醫療保健業務方面，公司目前的重點是在大灣區發展從線上合併至線下的企業醫療解決方案業務，在過去一年，公司在大灣區建立核心基礎設施方面達成重大的營運里程碑，開始達到羣聚效應。GOLD金牌培訓課程的受訓醫生數目現已超過1,250人而合約PPP診所數目超過150間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
